Myocardial Infarction With Non-Obstructive Coronary Arteries in the Greek Population

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-01

Study Completion Date

2024-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The MINOCA-GR registry will be the first nationwide study aiming to obtain data regarding prevalence, demographics, clinical profile, previous anginal status, presence of cardiovascular risk factors, management and outcomes in patients with Myocardial Infarction with Non-Obstructive Coronary Arteries. An additional purpose of the registry is to highlight, for the first time worldwide to the best of the investigator's knowledge, the role of cardiac computed tomography angiography for risk stratification and personalized therapeutic approach in MINOCA patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Etiologic Mechanisms, Myocardial Changes and Prognosis of Patients With MINOCA

NCT04538924

Myocardial Infarction With Nonobstructive Coronary Arteries

UNKNOWN NA

Prevalence of Myocarditis in Patients Suspected Myocardial Infarction With Non-Obstructive Coronary Arteries

NCT06966531

Prevalence of Myocarditis in MINOCA Patients

NOT_YET_RECRUITING

Prognostic Significance of CMR-Confirmed Infarct in MINOCA Patients from Sweden and Australia

NCT06889428

MINOCA

COMPLETED

Impact of Triglyceride-Glucose Index on Cardiovascular Outcomes in Patients Presented With MINOCA

NCT06066177

Major Cardiovascular Events

NOT_YET_RECRUITING

Cardiac Structure, Function, and Clinical Manifestations in MINOCA

NCT03572023

Acute Coronary Syndrome Myocardial Infarction

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

MINOCA occurs in 5%-10% of all patients with Acute Myocardial Infarction (AMI) and these patients are younger and more often women in comparison with patients with AMI and obstructive Coronary Artery Disease (CAD). The underlying pathophysiological mechanisms are poorly understood, although several different mechanisms have been proposed, including plaque disruption, spasm, thromboembolism, dissection, microvascular dysfunction and ischemic myocardial injury attributable to supply/demand mismatch. In most, but not all, studies of prognosis, MINOCA patients had better outcomes than their AMI counterparts with coronary artery disease but faced a high risk for recurrent events, with one study finding that 25% of patients with MINOCA experience angina in the following year. Optimal patient management requires early diagnosis as well as understanding which of the myriad of mechanisms (atherosclerotic or non-atherosclerotic as well as a combination of both) may be underlying the initial diagnosis. The effects of secondary preventive treatments proven beneficial in patients with classical type I AMI are unknown in MINOCA patients; randomized clinical trials, and large observational studies, as well, evaluating different treatments in MINOCA patients do not exist. Hence, evidence-based guidelines for treatment of MINOCA are lacking. Elucidating the associations between different treatments and outcome may also increase the understanding of underlying mechanisms of MINOCA. The underlying mechanisms strongly determine prognosis and more importantly, therapeutic interventions as well as their success.

Likewise, multimodality imaging could provide new insights into the management of MINOCA patients. The current research reveals the utility of Cardiac Magnetic Resonance for diagnosis and risk stratification of suspected MINOCA patients but at the same time shows how much more information is needed to further characterize risk and ultimately develop therapeutic approaches to alter its natural history. Computed tomography has a suite of strengths including diagnosis of CAD, identification of plaque characteristics, morphology and perfusion data, and even possibly delayed enhancement; its ability to detect nonobstructive coronary disease by way of visualizing not only the lumen but also plaques is very helpful in our efforts trying to understand microvascular disease, plaque erosion, and myocardial infarction with no obstructive coronary artery. Furthermore, up until recently, high-risk plaque features and lesion specific ischemia are thought to be not directly related. However, emerging evidence suggests a possible relationship between high-risk plaque features, particularly low attenuation plaque volume and positive remodeling, with lesion specific ischemia by fractional flow reserve. Such relationship is independent of degree of luminal stenosis. As a result of the above, it is obvious that Cardiac Computed Tomography Angiography (CCTA) may have a potential role in some selected patients with MINOCA, depending on their clinical picture and stability.

Regarding Greece, the MINOCA-GR registry will be the first prospectively enrolling medical database of this magnitude.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myocardial Infarction Non-Obstructive Coronary Atherosclerosis Ischemic Heart Disease Angina Pectoris Coronary Microvascular Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MINOCA patients

Prevalence, demographics, clinical profile, previous anginal status, presence of cardiovascular risk factors, management and outcomes in consecutive patients with Myocardial Infarction with Non-Obstructive Coronary Arteries admitted to study clinical sites

MINOCA registry

Intervention Type OTHER

Prevalence, demographics, clinical profile, anginal status, presence of cardiovascular risk factors, management and outcomes

CCTA Phenotypes

Intervention Type DIAGNOSTIC_TEST

1. Complete normal coronary arteries
2. Diffuse non-obstructive coronary artery disease
3. Non-obstructive high-risk plaques
4. Myocardial bridges

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MINOCA registry

Prevalence, demographics, clinical profile, anginal status, presence of cardiovascular risk factors, management and outcomes

Intervention Type OTHER

CCTA Phenotypes

1. Complete normal coronary arteries
2. Diffuse non-obstructive coronary artery disease
3. Non-obstructive high-risk plaques
4. Myocardial bridges

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients older than 18 years
2. Patients without known history of coronary artery disease
3. Patients with acute coronary syndrome with and/or without ST-segment elevation who underwent coronary angiography within 24h after onset of the disease
4. Absence of obstructive coronary atherosclerosis (normal coronary arteries or plaques \<50% stenosis) based on the results of invasive coronary angiography
5. Subject has provided written informed consent
6. Subject is willing to comply with study follow-up requirements

Exclusion Criteria

1. Patients \< 18 years old at time of coronary angiography
2. Patients with a previous history of coronary artery disease and/or prior revascularization
3. Patients with serious concurrent disease and life expectancy of \< 1 year
4. Patients who refuse to give written consent for participation in the study
5. In the investigator's opinion, subject will not be able to comply with the follow-up requirements
6. Subject is pregnant and/or breastfeeding or intends to become pregnant during the study
7. Subject has a known allergy to contrast agent that cannot be adequately pre-medicated

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No